Fever with thrombocytopenia syndrome (SFTS) is a newly emerged infectious disease in recent years, and its pathogen is SFTS virus, a new genus of virus of the family Bunyaviridae, the white lacewing virus. It is currently widespread in our city and has a high number of recent severe cases. These patients develop multiple organ failure in a short time based on fever, and in severe cases, it can even be life-threatening. Therefore, how to better improve the cure rate of patients has become a challenge before us. In this regard, we have reviewed the relevant literature, and through the experience accumulated by actively resuscitating critically ill patients, we have collated and analyzed the two “magic weapons” for the treatment of severe fever with thrombocytopenia syndrome, namely, the sedative propecia and platelets. The reasons are as follows: for severe viral infections, IV propecia is an eternal topic, so I will not elaborate here! (Note: Propecia is transfused within 7 days of onset if possible) As for platelet drip, it is not yet clearly proposed in all the literature. However, after our clinical application, it has been effective, and combined with the current theories proposed by experts, we explain this as follows: In the current theoretical system proposed by experts, it is stated that SFTS virus can adhere to platelets, which can be recognized and engulfed by splenic macrophages, leading to a decrease in platelets. For this reason we believe that according to this theory if we transfuse platelets then the ability of platelets to adhere to the virus will be significantly enhanced and after being adhered to by platelets the virus will no longer be able to enter the relevant target organ for replication (SFTS virus can replicate in a variety of cell types but its main target is reticulocytes). At the same time, the body’s immune function is strengthened by our IV propecia, and the ability to kill the virus is then enhanced. This two-pronged approach is sure to get twice the result with half the effort. Now that the virus has been eliminated, what more can be said about the return of the disease? Fever with thrombocytopenia syndrome can lead to coagulation dysfunction, resulting in complications such as DIC and intracranial hemorrhage, and once bleeding DIC or intracranial hemorrhage, the mortality rate is almost 100%. Therefore, early and timely application of platelets can play an important role in the prevention of DIC and intracranial hemorrhage. Of course, platelets are blood products after all, it is impossible to infuse without principle. After repeated arguments, we believe that platelets less than 40*109/L will be given platelet transfusion. If we wait until the platelets drop to a low level and then transfuse platelets, the virus will have already entered the target organs for massive replication and formation of viremia, even if a large number of platelets are transfused, there will already be a feeling of the 15th day of the first month. Of course, other organ failure can be treated symptomatically (the disease first involves the liver and heart, then the central nervous system, lungs and kidneys).